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doi:10.101Long-Term Follow-Up of an Intensified Myeloablative
Conditioning Regimen with In Vivo T Cell Depletion
Followed by Allografting in Patients with Advanced
Multiple Myeloma
Nicolaus Kro¨ger,1 Hermann Einsele,2 Gu¨nter Derigs,3 Hannes Wandt,4
Andreas Kru¨ll,5 Axel Zander1We report long-term results after a median follow-up of 105 months in 18 patients with multiple myeloma
who received an intensified myeloablative conditioning regimen regimen consisting of modified total body
irradiation, busulfan, cyclophosphamide, and antithymocyte globulin, followed by allogeneic stem cell trans-
plantation (SCT). Grade II-IV acute graft-versus-host disease occurred in 7 patients (44%), and treatment-
related mortality was 17%. Complete remission (CR) with negative immunofixation after allogeneic SCT
occurred in 53% of the patients. For all patients, the estimated overall survival at 12 years was 50% (95%
confidence interval [CI], 26%-74%), and the estimated event-free survival (EFS) was 35% (95% CI, 23%-
57%). Those patients who achieved CR after SCT had a 12-year estimated PFS of 60%, whereas none of
the patients without CR remained progression-free. Our data indicate that an intensified myeloablative
conditioning regimen followed by allogeneic SCT can produce long-term survival and freedom from disease
in patients with multiple myeloma who achieve CR.
Biol Blood Marrow Transplant 16: 861-864 (2010)  2010 American Society for Blood and Marrow TransplantationKEY WORDS: Antithymocyte globulin, Multiple myeloma, Allogeneic stem cell transplantation, Myeloabla-
tive conditioning regimen, Total marrow irradiationINTRODUCTION
Compared with other treatment modalities for
multiple myeloma (MM), allogeneic stem cell trans-
plantation (SCT) induces the highest rate of clinical
and molecular complete remission (CR) [1], resulting
in long-term freedom from disease in about 30%-
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(TRM), SCT is performed only in younger patients,
and even in those patients, it has not become the stan-
dard of care. Since the introduction of reduced-
intensity conditioning (RIC) regimens, allogeneic
SCT is more widely used to treat MM even in elderly
patients and in patientswith unrelated donors [4]. AEu-
ropean Group for Blood and Marrow Transplantation
(EBMT) study comparing RIC with myeloablative
(MA) conditioning showed lower nonrelapse mortality
for RIC transplantation, but also lower progression-
free survival (PFS) because of a higher risk of relapse
[4]. The same trial also reported a higher rate of CR as-
sociated with MA conditioning compared with RIC.
StandardMAconditioning regimens have improved,
especially with respect to TRM. The EBMT reported
better survival for MM patients undergoing SCT after
1994 compared with those did so before 1994 [5].
More recently, smaller phase II studies usingMA condi-
tioning reported TRM rates of\20%, suggesting only
amarginal difference inTRMbetweenMAconditioning
and RIC [6,7].
In 2003, we reported on the toxicity and efficacy
of an intensified MA conditioning regimen consisting
of modified total body irradiation (total marrow861
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862 Biol Blood Marrow Transplant 16:861-864, 2010N. Kro¨ger et al.irradiation), busulfan (9-12 mg/kg), cyclophospha-
mide (120 mg/kg), and antithymocyte globulin
(ATG), followed by allogeneic SCT, in 18 patients
with advanced MM at a median follow-up of 41
months (range, 8-84 months) [8]. Here we update
the results after a median follow-up of 105 months
(8.7 years), to explore the long-term and potential cu-
rative effect of this treatment approach.PATIENTS AND METHODS
Between 1995 and 2001, 18 patients (14 males and
4 females; median age, 44 years; range, 29-53 years)
were enrolled in this multicenter phase I/II trial.
Disease status before allogeneic SCT was partial
remission (PR) in 14 patients, no change in 2 patients,
and progressive disease in 2 patients. The median
number of previous chemotherapy cycles was 6 (range,
4-18) (Table 1). One patient relapsed from previous
high-dose chemotherapy and autologous SCT. Six pa-
tients had previous radiation therapy; 3 of these pa-
tients were not eligible for subsequent total marrow
irradiation. The median ß2 microglobulin serum level
at diagnosis was 3.1 mg/dL (range, 1.7-11 mg/dL).
The median time from diagnosis to transplantation
was 12 months (range, 6-144 months). The stem cell
source was bone marrow in 13 patients and peripheral
blood stem cells in 5 patients. Fifteen patients received
conditioning with total marrow irradiation, 900 cGy,
given over 3 days in 6 fractions, followed by busufan
12 mg/kg (n 5 4) or 9 mg/kg (n 5 11) and cyclophos-
phamide (120 mg/kg). Three of the patients with pre-
vious radiation therapy received only busulfan (14 mg/
kg) and cyclophosphamide (120mg/kg). Seventeen pa-
tients had an HLA-identical sibling, and 1 patient re-
ceived stem cells from an HLA-matched (8/8)
unrelated donor. To prevent acute and chronic graft-
versus-host disease (aGVHD, cGVHD), all patients
received rabbit ATG (Fresenius, Bad Homburg, Ger-
many) at a dose of 30 mg/kg over 12 hours on days -3,
-2, and -1. Further GVHD prophylaxis included cy-
closporine A and a short course of methotrexate (10
mg/m2 on days 11, 13, and 16).RESULTS AND DISCUSSION
Grade II-IV aGVHD occurred in 7 patients
(44%). Severe (grade III-IV) aGVHD developed in
1 patient (6%). The major toxicity was mucositis grade
II in 10 patients and grade III in 2 patients. Three
patients died of therapy-related causes (GVHD, sepsis,
and multiorgan failure), resulting in a TRM of 17%.
CR with negative immunofixation after allogeneic
SCT was seen in 8 patients (53%), and PR was seen
in 7 patients (47%), for an overall response rate of
100%. The high remission rate might have been
Figure 1. OS (A) and event-free survival (B) of all patients, and event-
free survival according to achievement of CR versus nonachievement of
CR (C).
Biol Blood Marrow Transplant 16:861-864, 2010 863Allografting in Multiple Myelomarelated to the use of high-dose rabbit ATG, which is
cytotoxic in myeloma cells and improves remission
status in patients with MM [9,10]. Three of the
patients with PR received a donor lymphocyte
infusion (DLI) for further tumor reduction after
SCT; 2 of these patients converted to CR, which
increased the rate of CR to 67%. Two patients were
lost to follow-up, 1 patient who relapsed 23 months af-
ter SCT and 1 patient who was in CR 25 months after
SCT.No further TRM occurred during follow-up, sug-
gesting that at least in younger patients, MA condi-
tioning results in lower mortality, as has been
reported in EBMT studies [5,11]. During the follow-
up period, 8 of 15 evaluable patients experienced re-
lapse or progression, including 4 of 5 patients with
PR after SCT (80%) and 4 of 10 patients with CR after
SCT (40%). Only 3 of the 8 patients who relapsed
were alive at the time of follow-up (including 1 patient
lost to follow-up at 23 months), supporting the
hypothesis that achievement of CR is important to
long-term survival. Six of the 10 long-term survivors
experienced cGVHD, 3 with extensive disease. After
a median follow-up of 105 months (range, 23-145
months), for all patients, the estimated overall survival
(OS) at 12 years was 50% (95% confidence interval
[CI], 26%-74%), and the estimated EFS was 35%
(95% CI, 23%-57%) (Figure 1). Subgroup analysis
showed that those patients who achieved CR after
SCT had an estimated 12-year EFS of 60%, whereas
none of the patients without CR remained
progression-free (Figure 1).
Along with achievement of CR after SCT, target-
ing CR in those patients who did not achieve CR after
SCT also seems reasonable. This is supported by the
fact that 2 patients who received DLI reduction
8 months and 14 months after SCT then converted
to CR, which has persisted for 10 years and 12 years,
respectively [12].
Even though this is only a small phase II study,
the long-term results reveal some conclusions and
considerations for future clinical trials:
1. MA conditioning followed by allogeneic SCT for
younger patients does not result in excessive TRM
and induces a high rate of CR.
2. High-dose ATG given in HLA-identical sibling
SCT resulted in a low rate of severe aGVHD and
seems to not be associated with an increase risk of
relapse.
3. The likelihood of long-term survival and freedom
from disease is greater in patients who achieve CR
after SCT.
4. Achievment of CR is crucial for long-term survival,
and future studies should include posttransplanta-
tion therapy for patients in incompete remission
with adoptive immunotherapy (ie, DLI) alone or
in combination with novel agents to target CR
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